Edgewise Therapeutics
EWTX
94 hedge funds and large institutions have $633M invested in Edgewise Therapeutics in 2022 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 36 increasing their positions, 22 reducing their positions, and 6 closing their positions.
267% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 6
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
64% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 22
56% more capital invested
Capital invested by funds: $406M → $633M (+$228M)
21% more funds holding
Funds holding: 78 → 94 (+16)
2.01% more ownership
Funds ownership: 102.8% → 104.8% (+2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$52.2M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$34.1M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$17M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$11.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$8.06M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$2.34M |
| 3 |
Barclays
London,
United Kingdom
|
-$2.12M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.19M |
| 5 |
Bank of New York Mellon
New York
|
-$944K |
EWTX Hedge Fund Activity: Q3 2022 in Review
94 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q3 2022, worth a combined $633M — up 56% from $406M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new EWTX positions and 6 closed out — a net gain of 16 holders — while 36 added to existing stakes and 22 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $52.2M. The largest seller was Cormorant Asset Management, cutting an estimated $8.06M.
- 94 institutional investors held Edgewise Therapeutics (EWTX) as of Q3 2022, up from 78 in Q2 2022.
- Funds reported $633M of Edgewise Therapeutics stock for Q3 2022, up 56% quarter-over-quarter.
- 22 funds opened new Edgewise Therapeutics positions in Q3 2022 and 6 closed out, a net change of +16 holders.
- The largest Edgewise Therapeutics buyer in Q3 2022 was Fidelity Investments, an estimated $52.2M added.
- The largest Edgewise Therapeutics seller in Q3 2022 was Cormorant Asset Management, an estimated $8.06M sold.
Based on aggregated 13F filings for Q3 2022.